Lexicon Pharmaceuticals, Inc.
LXRX · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.06 | -0.07 | -1.87 | 2.05 |
| FCF Yield | -76.08% | -47.99% | -28.49% | -15.38% |
| EV / EBITDA | -1.51 | -2.58 | -3.30 | -5.91 |
| Quality | ||||
| ROIC | -77.14% | -86.23% | -59.12% | -75.60% |
| Gross Margin | 98.02% | 92.94% | -207.19% | -18,371.81% |
| Cash Conversion Ratio | 0.89 | 0.91 | 0.87 | 0.99 |
| Growth | ||||
| Revenue 3-Year CAGR | 506.96% | 59.27% | -82.04% | -90.26% |
| Free Cash Flow Growth | -10.74% | -80.05% | -2.20% | 38.32% |
| Safety | ||||
| Net Debt / EBITDA | -0.23 | -0.51 | -0.09 | 0.71 |
| Interest Coverage | -12.65 | -13.11 | -36.24 | -108.59 |
| Efficiency | ||||
| Inventory Turnover | 2.67 | 0.22 | 0.00 | 0.00 |
| Cash Conversion Cycle | -8,592.41 | -59,845.81 | -8,812.13 | -43.54 |